6. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition for oral administration comprising as an active ingredient a compound of claim 4 and a pharmaceutically acceptable carrier.

~~10. 9. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 5.~~

~~10. The method of claim 9, wherein said PI3K related disease or disorder is a cell proliferative disorder.~~

~~11. The method of claim 10 wherein the cell proliferative disorder is a cancer.~~

~~12. The method of claim 11, wherein the cell proliferative disorder is selected from the group consisting of papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, coloreetal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.~~

~~13. A method of treating an HDAC mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.~~

~~14. A method of treating a disease mediated by both PI3K and HDAC comprising administering to a subject in need thereof a pharmaceutical composition of claim 5.~~

15. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 7.

16. The method of claim 15 wherein said PI3K related disease or disorder is a cell proliferative disorder.

17. The method of claim 16 wherein the cell proliferative disorder is a cancer.

18. The method of claim 16 wherein the cell proliferative disorder is selected from the group consisting of papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

19. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.

20. A method of treating a disease mediated by both PI3K and HDAC comprising administering to a subject in need thereof a pharmaceutical composition of claim 7.